Quality assessment of autografting by probability evaluation: Model estimation by clinical end-points in newly diagnosed multiple myeloma patients

Cytotherapy

Volumn 8, Issue 1, 2006, Pages 79-88

  Roer, O ^a   Hammerstrom J ^b   Lenhoff, S ^c   Mylin, A K ^a   Knudsen, L M ^a   Rasmussen, T ^a   Johnsen, H E ^a,d  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

^d AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Autografting; Multiple myeloma; Quality assessment; Translational research

Indexed keywords

ANTIBIOTIC AGENT; CREATININE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; HEMOGLOBIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; VINCRISTINE;

ADULT; AGED; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BLOOD TRANSFUSION; BONE MARROW CELL; CANCER RECURRENCE; CD34 SELECTION; CELL COUNT; CLINICAL TRIAL; CREATININE BLOOD LEVEL; ETHNIC DIFFERENCE; HEMOGLOBIN DETERMINATION; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE MYELOMA; PROBABILITY; PROGNOSIS; QUALITY CONTROL; RETROSPECTIVE STUDY; SAFETY; SEX DETERMINATION; STATISTICAL ANALYSIS; STATISTICAL MODEL; TREATMENT RESPONSE;

CLINICAL TRIALS; ENDPOINT DETERMINATION; HUMANS; MIDDLE AGED; MODELS, BIOLOGICAL; MULTIPLE MYELOMA; PROBABILITY; PROGNOSIS; RETROSPECTIVE STUDIES; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 33344460815     PISSN: 14653249     EISSN: None     Source Type: Journal    
DOI: 10.1080/14653240500499549     Document Type: Article

References (26)

1. Attal, M and Harousseau, JL and Stoppa, AM and (1996) A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome [comments] N Engl J Med, 335, pp. 91 - 7.
2. Barlogie, B and Jagannath, S and Vesole, DH and (1997) Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma Blood, 89, pp. 789 - 93.
3. Lenhoff, S and Hjorth, M and Holmberg, E and (2000) Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: A population-based study. Nordic Myeloma Study Group Blood, 95, pp. 7 - 11.
4. Hjorth, M and Holmberg, E and Rodjer, S and (1999) Survival in conventionally treated younger (Eur J Haematol, 62, pp. 271 - 7.
5. + cell analysis: Technical recommendations for progenitor cell enumeration in leukapheresis from multiple myeloma patients. Nordic Myeloma Study Group Laboratories J Hematother, 4, pp. 21 - 8.
6. Johnsen, HE and Knudsen, LM. (1996) Nordic flow cytometry standards for CD34+ cell enumeration in blood and leukapheresis products: Report from the second Nordic Workshop. Nordic Stem Cell Laboratory Group (NSCL-G) J Hematother, 5, pp. 237 - 45.
7. + cell enumeration in blood and autografts: Report from the third workshop. J Hematother 1999;8:15-28.
8. Gulbrandsen, N and Wisloff, F and Brinch, L and (2001) Health-related quality of life in multiple myeloma patients receiving high-dose chemotherapy with autologous blood stem-cell support Med Oncol, 18, pp. 65 - 77.
9. Serke, S and Johnsen, HE. (2001) A European reference protocol for quality assessment and clinical validation of autologous haematopoietic blood progenitor and stem cell grafts Bone Marrow Transplant, 27, pp. 463 - 70.
10. LenhoffS, HjorthM, TuressonIet al.Impact of age on survival after high-dose therapy with autologous stem cell support in newly diagnosed multiple myeloma: A population-based study. Br J Haematol in press.
11. Rasmussen, T and Jensen, L and Honore, L and (1999) Circulating clonal cells in multiple myeloma do not express CD34 mRNA, as measured by single-cell and real-time RT-PCR assays Br J Haematol, 107, pp. 818 - 24.
12. Rasmussen, T and Jensen, L and Honore, L and Johnsen, HE. (2000) Frequency and kinetics of polyclonal and clonal B cells in the peripheral blood of patients being treated for multiple myeloma Blood, 96, pp. 4357 - 9.
13. JohnsenHE. EBMT quality assessment of haematopoietic stem cell grafts sub-committee. 2003. http://www.ebmt.org/7Directory/committees/ qahscg.htm The European Group of Blood and Marrow Transplantation. Barcelona, Spain.
14. Johnsen, HE and Lanza, F. (2002) Quality assessment of autologous hematopoietic blood progenitor and stem cell grafting: A prospective registration study J Biol Regul Homeost Agents, 16, pp. 272 - 88.
15. Billadeau, D and Ahmann, G and Greipp, P and Van Ness, B. (1993) The bone marrow of multiple myeloma patients contains B cell populations at different stages of differentiation that are clonally related to the malignant plasma cell J Exp Med, 178, pp. 1023 - 31.
16. Corradini, P and Boccadoro, M and Voena, C and Pileri, A. (1993) Evidence for a bone marrow B cell transcribing malignant plasma cell VDJ joined to C mu sequence in immunoglobulin (IgG)- and IgA- secreting multiple myelomas J Exp Med, 178, pp. 1091 - 6.
17. Tricot, G and Gazitt, Y and Leemhuis, T and (1998) Collection, tumor contamination, and engraftment kinetics of highly purified hematopoietic progenitor cells to support high dose therapy in multiple myeloma Blood, 91, pp. 4489 - 95.
18. Schiller, G and Vescio, R and Freytes, C and (1998) Autologous CD34-selected blood progenitor cell transplants for patients with advanced multiple myeloma [comments] Bone Marrow Transplant, 21, pp. 141 - 5.
19. Lemoli, RM and Cavo, M and Fortuna, A. (1996) Concomitant mobilization of plasma cells and hematopoietic progenitors into peripheral blood of patients with multiple myeloma J Hematother, 5, pp. 339 - 49.
20. Kiel, K and Cremer, FW and Rottenburger, C and (1999) Analysis of circulating tumor cells in patients with multiple myeloma during the course of high-dose therapy with peripheral blood stem cell transplantation Bone Marrow Transplant, 23, pp. 1019 - 27.
21. Kiel, K and Cremer, FW and Ehrbrecht, E and (1998) First and second apheresis in patients with multiple myeloma: No differences in tumor load and hematopoietic stem cell yield Bone Marrow Transplant, 21, pp. 1109 - 15.
22. Brenner, MK and Rill, DR and Moen, RC and (1993) Gene-marking to trace origin of relapse after autologous bone-marrow transplantation Lancet, 341, pp. 85 - 6.
23. Vescio, R and Schiller, G and Stewart, AK and (1999) Multicenter phase III trial to evaluate CD34(+) selected versus unselected autologous peripheral blood progenitor cell transplantation in multiple myeloma Blood, 93, pp. 1858 - 68.
24. + cell enrichment by magnetic field, magnetic beads or chromatography separation Bone Marrow Transplant, 24, pp. 1329 - 36.
25. Harada, H and Kawano, MM and Huang, N and (1993) Phenotypic difference of normal plasma cells from mature myeloma cells Blood, 81, pp. 2658 - 63.
26. Baech, J and Roer, O and Johnsen, HE. (2003) Individual quality assessment of autografting by probability evaluation: A model estimated by analysis of graft-related end points in 204 patients with malignancies Bone Marrow Transplant, 31, pp. 453 - 8.